You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
RSV antibodies in profile
Respiratory syncytial virus (RSV) causes cold-like symptoms in healthy adults but can have serious complications in both the very young and elderly. No vaccine is approved for RSV, and although a prophylactic antibody, palivizumab, is available for high-risk infants, therapy is generally supportive. Now, Gilman et al. profile the human antibody response to the RSV fusion (F) glycoprotein. They find that the response is broad but that more potent antibodies tend to target the apex of the prefusion conformation of RSV F, suggesting this site as a putative vaccine target. Moreover, many of these antibodies were more potent than palivizumab and some cross-neutralized human metapneumovirus, making them candidates for new passive prophylactics.
- Copyright © 2016, American Association for the Advancement of Science
